

# Marina Keul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7829197/publications.pdf>

Version: 2024-02-01

14  
papers

509  
citations

1039406

9  
h-index

1058022

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

883  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 6643-6655.	2.9	12
2	Targeting Her2-insYVMA with Covalent Inhibitorsâ€”A Focused Compound Screening and Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11725-11755.	2.9	7
3	Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. <i>Chemical Science</i> , 2019, 10, 10789-10801.	3.7	25
4	Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14718-e14718.	0.8	1
5	Lessons To Be Learned: The Molecular Basis of Kinaseâ€™Targeted Therapies and Drug Resistance in Nonâ€™Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 2307-2313.	7.2	36
6	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	5.8	107
7	RASPELD to Perform Highâ€™End Screening in an Academic Environment toward the Development of Cancer Therapeutics. <i>ChemMedChem</i> , 2018, 13, 2065-2072.	1.6	5
8	Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2361-2372.	2.9	43
9	Characterization of Covalent-Reversible EGFR Inhibitors. <i>ACS Omega</i> , 2017, 2, 1563-1575.	1.6	18
10	Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5613-5637.	2.9	77
11	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	55
12	Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8801-8815.	2.9	7
13	Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7725-7744.	2.9	24
14	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6844-6863.	2.9	92